News

BLOG: Medtech Innovation Improving and Saving Lives

At Lexington Biosciences, we are passionate believers in medical technology (medtech) as a way of improving healthcare and quality of life for all.  Similarly, well known consumer brand giants are also gravitating towards the medtech space.  Just like us, they see a chance to help humanity and address a market that is nothing shy of

Read More

BLOG: Lexington Biosciences Applauds ACA and AHA Initiative to Lower Threshold for Hypertension and Recognition that More Diagnostics are Needed to Combat Heart Disease

Last November, the American College of Cardiology and American Heart Association jointly lowered their definition of hypertension from the previous 140/90 blood pressure reading down to 130/80.  Unfortunately, there isn’t necessarily a “one size fits all” standard due to an array of factors associated with high blood pressure, but there certainly is a well-known correlation

Read More

Lexington Biosciences Announces Amended Terms to Previously Announced Brokered Financing

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, British Columbia, June 11, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”) announces that it has amended the terms of its previously announced brokered private placement being led by Gravitas Securities Inc. and Canaccord Genuity Corp. (the “Agents”) (see news release

Read More

BLOG: You Don’t Want Your First Sign of a Problem to be a Heart Attack

Nearly everyone has a story about someone close to them that passed away suddenly due to cardiac arrest, or someone who had a stroke that left them disabled, no longer the person they were the day before.  Management here at Lexington Biosciences is no different.  Our founders and leadership team have also gotten that gut-wrenching

Read More

Article: Lexington Biosciences is Set to Help Predict Cardiovascular Disease

Lexington Biosciences Inc. (CSE:LNB) (OTC:LXGTF) plans to commercialize an at-home product to better predict whether a person is at risk for cardiovascular disease Angela Harmantas | May 31, 2018 | SmallCapPower: Cardiovascular disease is leading cause of death in North America, and yet, nearly one-third of those deaths are preventable. Annually, over 1.5 million people

Read More

VIDEO: Lexington Biosciences Founder: We Have a Cardiovascular Disease Prediction Device

Lexington Biosciences, Inc.’s (CSE:LNB) Donald McInnes discusses the Company’s regulatory and commercialization efforts Lexington Biosciences Founder: We Have a Cardiovascular Disease Prediction Device In an interview with SmallCapPower, Lexington Biosciences, Inc. (CSE:LNB) Founder and Board Advisor Donald McInnes explains that Lexington’s technology helps predict cardiovascular disease, which is known as the “silent killer.” Find out more about

Read More

Lexington Biosciences Digital Newsletter V1

The Wellness Sector Revolution and HeartSentry by Lexington Bioscience Dear Friends and Shareholders, Today, the Lexington Biosciences team is bringing together some items and articles of interest all in one location in order to inform and educate about an extraordinary story going on around us. Some of you may already know all about our company,

Read More

Lexington Engages with Major Canadian University and Provides Clinical Trial Update

Company commences HeartSentry clinical research collaboration with University of British Columbia VANCOUVER, British Columbia, May 08, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise it has engaged with a dedicated research team at The University of British Columbia (“UBC”) to perform an independent analysis and

Read More

Lexington Announces Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN VANCOUVER, B.C., May 04, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”) is pleased to announce that it has appointed Gravitas Securities Inc. and Canaccord Genuity Corp. (collectively, the “Agents”) to sell, by way of a private placement on a best efforts

Read More

Lexington Releases Audited Consolidated Financial Statements

VANCOUVER, British Columbia, April 30, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, has released its audited Consolidated Financial Statements and Management, Discussion and Analysis for the year ended December 31, 2017, both of which are available for review via the Company’s website at www.lexingtonbiosciences.com; or via SEDAR at www.sedar.com. Overall

Read More

1 2 3 4

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News